Want to see TSE:MGRO full AI Analyst Report?
MustGrow Biologics (MGRO) AI Stock Analysis
MustGrow Biologics
(TSXV:MGRO)
Persistent losses and substantial negative cash flow are the most significant weaknesses, with low leverage providing only limited balance-sheet support. The price remains below all supplied moving averages, and the negative P/E offers no valuation support. The weighted result is 39 out of 99.
MustGrow Biologics (MGRO) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 18.66M
- Dividend Yield
- ―
- Average Volume (3M)
- 37.60K
- Price to Earnings (P/E)
- -3.7
- Beta (1Y)
- 0.66
- Revenue Growth
- -54.59%
- EPS Growth
- 10.76%
- Country
- Canada
- Employees
- 8
- Sector
- Basic Materials
- Sector Strength
- 61
- Industry
- Agricultural Inputs
MustGrow Biologics Business Overview & Revenue Model
Company Description
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely deri...
How the Company Makes Money
MustGrow makes money primarily by monetizing its biologic technology through commercialization arrangements rather than operating a large direct-to-farm distribution business. Revenue is expected to come from (a) licensing its technology/IP to establ...
MustGrow Biologics Financial Statement Overview
Summary
Revenue is volatile, operating and net losses remain substantial, and operating and free cash flow are persistently negative. Low leverage and improved equity provide some support, but ongoing cash burn and reliance on external financing justify a very weak score.
Income Statement
28NegativeBalance Sheet
42NeutralCash Flow
22Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.19M | 8.29M | 398.02K | 4.71M | 6,479 | 12.87K |
| Gross Profit | 1.68M | 1.41M | 300.75K | 4.33M | 6,479 | 12.87K |
| EBITDA | -4.20M | -6.20M | -4.89M | -676.94K | -5.56M | -3.01M |
| Net Income | -5.57M | -7.26M | -4.89M | -676.94K | -5.57M | -3.06M |
Balance Sheet | ||||||
| Total Assets | 7.16M | 3.09M | 5.42M | 6.94M | 7.13M | 9.70M |
| Cash, Cash Equivalents and Short-Term Investments | 4.37M | 918.77K | 3.00M | 6.82M | 7.02M | 9.62M |
| Total Debt | 515.57K | 584.13K | 517.99K | 759.33K | 759.33K | 749.27K |
| Total Liabilities | 2.11M | 2.23M | 3.25M | 1.35M | 1.90M | 1.25M |
| Stockholders Equity | 5.05M | 867.10K | 2.17M | 5.58M | 5.24M | 8.46M |
Cash Flow | ||||||
| Free Cash Flow | -4.34M | -6.56M | -3.58M | -294.76K | -3.26M | -2.41M |
| Operating Cash Flow | -2.85M | -5.06M | -3.58M | -294.76K | -3.26M | -2.41M |
| Investing Cash Flow | -1.49M | -1.50M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 6.89M | 4.48M | -241.34K | 95.75K | 653.75K | 8.72M |
MustGrow Biologics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MGRO, the sentiment is Negative. The current price of 0.36 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.42, and below the 200-day MA of 0.50, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.15 is Neutral, neither overbought nor oversold. The STOCH value of 17.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MGRO.
MustGrow Biologics Peers Comparison
Overall Rating
TSE:NTR71Outperform
TSE:PLAN60Neutral
TSE:NPK48Neutral
TSE:GSP40Underperform- TSE:MGRO39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:NTR | 71Outperform | CAD 46.17B | 14.05 | 9.38% | 3.17% | 7.77% | 76.65% |
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| TSE:PLAN | 60Neutral | CAD 34.01M | 41.22 | 5.11% | ― | 18.41% | -71.10% |
| TSE:NPK | 48Neutral | CAD 38.38M | -2.90 | -59.51% | ― | -20.60% | -8.43% |
| TSE:GSP | 40Underperform | CAD 62.19M | -22.81 | -27.00% | ― | ― | 13.85% |
| TSE:MGRO | 39Underperform | CAD 25.36M | -3.71 | -218.75% | ― | -54.59% | 10.76% |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:MGRO | Mustgrow Biologics Corp. | 0.36 | -0.35 | -49.30% | |
| TSE:PLAN | Progressive Planet Solutions Inc. | 0.30 | 0.02 | 5.17% | |
| TSE:GSP | Gensource Potash | 0.13 | 0.07 | 100.00% | |
| TSE:NPK | Verde Agritech | 0.68 | -0.45 | -39.82% | |
| TSE:NTR | Nutrien | 96.96 | 22.75 | 30.65% |
MustGrow Biologics Corporate Events
MustGrow Deepens Bayer Partnership With Webcast as Milestone Deal Advances
PositiveMustGrow Biologics Corp., a Canadian developer of mustard-based biological crop inputs, is expanding its presence in sustainable agriculture with organic biofertility, biostimulant, and biocontrol products tailored to protect soil health and support...
MustGrow Biologics Bolsters Finance Team and Grants Equity-Based DSUs
PositiveMustGrow Biologics has strengthened its finance leadership by appointing Tyler Reinheimer, CPA, as Director, Finance, while its board has approved the issuance of 1,126,954 deferred share units to non-executive directors and the new officer. The DSUs...
MustGrow Turns Q2 Profit as Licensing Revenue Offsets TerraSante Logistics Drag
PositiveMustGrow Biologics reported second-quarter 2026 results showing TerraSante sales of $75,000, down from $313,000 a year earlier, with gross margin squeezed by costly air freight used to meet demand amid capacity ramp-up at contract manufacturers. Desp...
MustGrow Secures First Bayer Milestone in Mustard-Based Biocontrol Deal
PositiveMustGrow Biologics has received its first development milestone payment from Bayer AG under a license and collaboration agreement signed in December 2023. The deal grants Bayer rights to develop and commercialize MustGrow’s mustard-based biocon...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 17, 2026